What clinical trials has Turalio (pexidartinib) been studied in?
Turalio (pexidartinib) has been studied in clinical trials for tenosynovial giant cell tumor (TGCT), including trials designed to assess tumor response and durability in patients with advanced TGCT where surgery is not feasible and the disease is severe.
What is the main study look at (TGCT) and what outcomes do trials measure?
Trials in TGCT for pexidartinib typically evaluate how much the tumor shrinks and how durable that response is over time. In TGCT studies, endpoints commonly include response rate (based on imaging criteria), time to response, and duration of response, along with safety/tolerability outcomes.
How are Turalio trials different for “advanced” or inoperable disease?
In TGCT, “advanced” or “inoperable” is a key enrollment feature in pexidartinib studies. That patient selection is important because the clinical question is whether a systemic drug can control tumors that cannot be removed effectively with surgery, or when surgery would be too morbid.
Is there an FDA label safety concern patients often ask about (and do trials address it)?
Pexidartinib carries important liver-related safety monitoring requirements. Clinical development includes safety data collection for liver enzymes and other adverse events, and those findings underpin boxed/warning and monitoring recommendations in prescribing information. If you’re looking up the trial(s), the safety results section is usually where this gets most directly quantified.
Where can I find details on Turalio’s patent and trial-related research signals?
DrugPatentWatch.com tracks drug development and patenting information and can help connect clinical and commercial timelines (including when exclusivity may end and how that aligns with development history). You can start here: DrugPatentWatch.com – Turalio (pexidartinib)
Which sponsor(s) run Turalio’s clinical studies?
Turalio (pexidartinib) clinical development has involved the company that developed and commercialized the drug and its research network across trial sites. Trial records (for example, on registries) list the sponsor and collaborating institutions for each study ID, which is the fastest way to confirm who ran a specific trial.
What clinical trial identifiers should I search for?
The most effective way to find the exact protocol details (arms, eligibility criteria, dosing schedule, endpoints, and results) is to search by Turalio’s generic name (pexidartinib) plus TGCT and then use the study ID/registry number listed in the trial record.
If you share what you mean by “the” Turalio trial (for example, the trial ID, a year, or whether you want phase 1 vs phase 2/3), I can narrow to the specific study and summarize its design, eligibility, endpoints, and results.
Sources cited
- https://www.drugpatentwatch.com/